In this section, we will focus on the strategy of combining PD1/PD-L1 immune checkpoint inhibitors with other therapeutic methods in the treatment of ccRCC, and analyze the clinical efficacy and safety, so as to provide reference for future clinical practice. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.